A service of StreetInsider.com
Ticker Symbol

Most Popular

AAPL 113.29
GOOG 630.38
MSFT 43.93
FB 91.01
BAC 16.36

Recently Added

GS 187.75
QID 35.07
SDS 22.01
CNFR 10.40
CAI 12.60

Gaining Speed

SDS 22.01
QID 35.07
TVIX 13.80
CPA 52.11
GS 187.75

ZIOPHARM Oncology (ZIOP) Reports Palifosfamide Hits PFS Events in Phase 3

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that the Phase 3 (PICASSO 3) trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma has reached its target number of progression-free survival (PFS) events. PICASSO 3 is an international, randomized, double-blind, placebo-controlled trial whose primary endpoint is PFS....

Read More




Get Alerted When News Hits On This Stock - FREE!